144 related articles for article (PubMed ID: 29631858)
1. Hormone Levels and Sexual Functioning After Risk-Reducing Salpingo-Oophorectomy.
Johansen N; Liavaag AH; Mørkrid L; Michelsen TM
Sex Med; 2018 Jun; 6(2):143-153. PubMed ID: 29631858
[TBL] [Abstract][Full Text] [Related]
2. Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy.
Johansen N; Liavaag AH; Tanbo TG; Dahl AA; Pripp AH; Michelsen TM
Gynecol Oncol; 2016 Jan; 140(1):101-6. PubMed ID: 26597462
[TBL] [Abstract][Full Text] [Related]
3. Sexual functioning more than 15 years after premenopausal risk-reducing salpingo-oophorectomy.
Terra L; Beekman MJ; Engelhardt EG; Heemskerk-Gerritsen BAM; van Beurden M; Roeters van Lennep JE; van Doorn HC; de Hullu JA; Van Dorst EBL; Mom CH; Slangen BFM; Gaarenstroom KN; van der Kolk LE; Collée JM; Wevers MR; Ausems MGEM; Van Engelen K; van de Beek I; Berger LPV; van Asperen CJ; Gomez Garcia EB; Maas AHEM; Hooning MJ; Aaronson NK; Mourits MJE; van Leeuwen FE
Am J Obstet Gynecol; 2023 Apr; 228(4):440.e1-440.e20. PubMed ID: 36403862
[TBL] [Abstract][Full Text] [Related]
4. Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy.
Johansen N; Liavaag AH; Iversen OE; Dørum A; Braaten T; Michelsen TM
Acta Obstet Gynecol Scand; 2017 May; 96(5):547-555. PubMed ID: 28236297
[TBL] [Abstract][Full Text] [Related]
5. Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study.
Vermeulen RFM; Beurden MV; Kieffer JM; Bleiker EMA; Valdimarsdottir HB; Massuger LFAG; Mourits MJE; Gaarenstroom KN; van Dorst EBL; van der Putten HWHM; Aaronson NK
Eur J Cancer; 2017 Oct; 84():159-167. PubMed ID: 28818705
[TBL] [Abstract][Full Text] [Related]
6. The effects of pre-operative menopausal status and hormone replacement therapy (HRT) on sexuality and quality of life after risk-reducing salpingo-oophorectomy.
Tucker PE; Bulsara MK; Salfinger SG; Tan JJ; Green H; Cohen PA
Maturitas; 2016 Mar; 85():42-8. PubMed ID: 26857878
[TBL] [Abstract][Full Text] [Related]
7. Sexual function, menopausal symptoms, depression and cancer worry in women with BRCA mutations.
Powell CB; Alabaster A; Le A; Stoller N; Armstrong MA; Raine-Bennett T
Psychooncology; 2020 Feb; 29(2):331-338. PubMed ID: 31654466
[TBL] [Abstract][Full Text] [Related]
8. Sexuality and quality of life in women with a prior diagnosis of breast cancer after risk-reducing salpingo-oophorectomy.
Tucker PE; Saunders C; Bulsara MK; Tan JJ; Salfinger SG; Green H; Cohen PA
Breast; 2016 Dec; 30():26-31. PubMed ID: 27592287
[TBL] [Abstract][Full Text] [Related]
9. Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.
Hall E; Finch A; Jacobson M; Rosen B; Metcalfe K; Sun P; Narod SA; Kotsopoulos J
Gynecol Oncol; 2019 Jan; 152(1):145-150. PubMed ID: 30414741
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of sexual dysfunction after risk-reducing salpingo-oophorectomy.
Tucker PE; Bulsara MK; Salfinger SG; Tan JJ; Green H; Cohen PA
Gynecol Oncol; 2016 Jan; 140(1):95-100. PubMed ID: 26545955
[TBL] [Abstract][Full Text] [Related]
11. Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines.
Vermeulen RFM; Korse CM; Kenter GG; Brood-van Zanten MMA; Beurden MV
Climacteric; 2019 Aug; 22(4):352-360. PubMed ID: 30905183
[No Abstract] [Full Text] [Related]
12. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis.
Marchetti C; De Felice F; Boccia S; Sassu C; Di Donato V; Perniola G; Palaia I; Monti M; Muzii L; Tombolini V; Benedetti Panici P
Crit Rev Oncol Hematol; 2018 Dec; 132():111-115. PubMed ID: 30447915
[TBL] [Abstract][Full Text] [Related]
13. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.
Gordhandas S; Norquist BM; Pennington KP; Yung RL; Laya MB; Swisher EM
Gynecol Oncol; 2019 Apr; 153(1):192-200. PubMed ID: 30661763
[TBL] [Abstract][Full Text] [Related]
14. Changes in Sex Steroids and Relation With Menopausal Complaints in Women Undergoing Risk-reducing Salpingo-oophorectomy.
van Winden LJ; Vermeulen RFM; van den Noort V; Gaarenstroom KN; Kenter GG; Brood-van Zanten MMA; Korse CM; van Beurden M; van Rossum HH
J Endocr Soc; 2022 Jun; 6(6):bvac069. PubMed ID: 35592509
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for sexual dysfunction in BRCA mutation carriers after risk-reducing salpingo-oophorectomy.
Chan JL; Senapati S; Johnson LNC; DiGiovanni L; Voong C; Butts SF; Domchek SM
Menopause; 2019 Feb; 26(2):132-139. PubMed ID: 30020253
[TBL] [Abstract][Full Text] [Related]
16. Does anti-Müllerian hormone predict change in menopausal symptoms following risk-reducing salpingo-oophorectomy? A prospective observational study.
Vermeulen RFM; van Beurden M; Gaarenstroom KN; Teunis T; Kieffer JM; Aaronson NK; Kenter GG; Korse CM
Climacteric; 2018 Dec; 21(6):574-580. PubMed ID: 30295077
[TBL] [Abstract][Full Text] [Related]
17. Severity and duration of menopausal symptoms after risk-reducing salpingo-oophorectomy.
Stuursma A; van Driel CMG; Wessels NJ; de Bock GH; Mourits MJE
Maturitas; 2018 May; 111():69-76. PubMed ID: 29673834
[TBL] [Abstract][Full Text] [Related]
18. A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer.
Fang CY; Cherry C; Devarajan K; Li T; Malick J; Daly MB
Gynecol Oncol; 2009 Mar; 112(3):594-600. PubMed ID: 19141360
[TBL] [Abstract][Full Text] [Related]
19. Cholesterol profile in women with premature menopause after risk reducing salpingo-oophorectomy.
Teixeira N; Mourits MJ; Oosterwijk JC; Fakkert IE; Absalom AR; Bakker SJL; van der Meer P; de Bock GH
Fam Cancer; 2019 Jan; 18(1):19-27. PubMed ID: 29881922
[TBL] [Abstract][Full Text] [Related]
20. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy.
Madalinska JB; van Beurden M; Bleiker EM; Valdimarsdottir HB; Hollenstein J; Massuger LF; Gaarenstroom KN; Mourits MJ; Verheijen RH; van Dorst EB; van der Putten H; van der Velden K; Boonstra H; Aaronson NK
J Clin Oncol; 2006 Aug; 24(22):3576-82. PubMed ID: 16877724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
